Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HARAMANDEEP SINGH

Allopathic & Osteopathic Physicians Psychiatry & Neurology Sleep Medicine

NPI
1154410967
CMS profile
234103
Location
SAN RAMON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$189,627.86

305 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 7; records 51–100 of 305 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HARAMANDEEP SINGH

NPI 1154410967 · CMS profile ID 234103

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Sleep Medicine

SAN RAMON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 7; records 51–100 of 305 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154410967?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HARAMANDEEP SINGH, NPI 1154410967, CMS profile ID 234103. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 305 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154410967?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HARAMANDEEP SINGH, NPI 1154410967, CMS profile ID 234103. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 305 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154410967?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HARAMANDEEP SINGH, NPI 1154410967, CMS profile ID 234103, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 305 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1154410967?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

305 matching records · $189,627.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 305 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 305.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $228.5011/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604713 CMS
JAZZ PHARMACEUTICALS INC. $125.7111/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604705 CMS
JAZZ PHARMACEUTICALS INC. $127.7411/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604743 CMS
JAZZ PHARMACEUTICALS INC. $121.3411/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604683 CMS
JAZZ PHARMACEUTICALS INC. $243.4511/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604707 CMS
JAZZ PHARMACEUTICALS INC. $17.6911/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604709 CMS
JAZZ PHARMACEUTICALS INC. $243.4811/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604745 CMS
JAZZ PHARMACEUTICALS INC. $17.6911/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604747 CMS
JAZZ PHARMACEUTICALS INC. $141.0011/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604749 CMS
JAZZ PHARMACEUTICALS INC. $141.0011/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604751 CMS
JAZZ PHARMACEUTICALS INC. $14.8311/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604687 CMS
JAZZ PHARMACEUTICALS INC. $41.6911/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604689 CMS
JAZZ PHARMACEUTICALS INC. $8.6011/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604691 CMS
JAZZ PHARMACEUTICALS INC. $4.8111/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604693 CMS
JAZZ PHARMACEUTICALS INC. $13.0011/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604695 CMS
JAZZ PHARMACEUTICALS INC. $123.3611/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604727 CMS
JAZZ PHARMACEUTICALS INC. $1,350.0011/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604527 CMS
JAZZ PHARMACEUTICALS INC. $23.0511/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604731 CMS
JAZZ PHARMACEUTICALS INC. $23.3211/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604733 CMS
JAZZ PHARMACEUTICALS INC. $14.9911/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604735 CMS
JAZZ PHARMACEUTICALS INC. $90.7211/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604699 CMS
JAZZ PHARMACEUTICALS INC. $153.6011/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604701 CMS
JAZZ PHARMACEUTICALS INC. $90.7211/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604737 CMS
JAZZ PHARMACEUTICALS INC. $153.6011/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604739 CMS
JAZZ PHARMACEUTICALS INC. $136.6011/06/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604703 CMS
JAZZ PHARMACEUTICALS INC. $136.6011/06/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604741 CMS
JAZZ PHARMACEUTICALS INC. $25.0011/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602943 CMS
JAZZ PHARMACEUTICALS INC. $26.3511/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602945 CMS
JAZZ PHARMACEUTICALS INC. $43.5911/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602947 CMS
JAZZ PHARMACEUTICALS INC. $4,050.0011/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603939 CMS
HARMONY BIOSCIENCES LLC $1,080.0010/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853088305 CMS
JAZZ PHARMACEUTICALS INC. $10.0010/29/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603955 CMS
JAZZ PHARMACEUTICALS INC. $247.2810/29/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603957 CMS
JAZZ PHARMACEUTICALS INC. $482.7610/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602497 CMS
JAZZ PHARMACEUTICALS INC. $139.7010/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602499 CMS
JAZZ PHARMACEUTICALS INC. $5.0610/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602503 CMS
JAZZ PHARMACEUTICALS INC. $597.2010/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602505 CMS
JAZZ PHARMACEUTICALS INC. $285.5210/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602507 CMS
JAZZ PHARMACEUTICALS INC. $471.5010/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603799 CMS
JAZZ PHARMACEUTICALS INC. $124.9910/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603947 CMS
JAZZ PHARMACEUTICALS INC. $84.9910/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603953 CMS
JAZZ PHARMACEUTICALS INC. $8.5310/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602909 CMS
JAZZ PHARMACEUTICALS INC. $19.7710/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602911 CMS
JAZZ PHARMACEUTICALS INC. $636.4110/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602913 CMS
JAZZ PHARMACEUTICALS INC. $38.9510/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602917 CMS
JAZZ PHARMACEUTICALS INC. $21.0010/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603049 CMS
JAZZ PHARMACEUTICALS INC. $71.7710/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603051 CMS
JAZZ PHARMACEUTICALS INC. $9.9510/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603053 CMS
JAZZ PHARMACEUTICALS INC. $4,950.0010/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603803 CMS
JAZZ PHARMACEUTICALS INC. $415.6910/26/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603797 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $102,903.06 211
PY2020 $132,934.31 216
PY2021 $189,627.86 305
PY2022 $173,911.35 247
PY2023 $242,441.71 296
PY2024 $184,532.82 195
PY2025 $53,675.48 47

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $223,181.14 53
PY2025 Principal investigator $12,582.16 45
PY2024 Recipient $112,846.17 34
PY2024 Principal investigator $79,913.70 56
PY2023 Recipient $65,558.93 17
PY2023 Principal investigator $29,435.67 23
PY2022 Recipient $16,130.05 2
PY2022 Principal investigator $68,217.32 3
PY2021 Recipient $6,463.00 1
PY2021 Principal investigator $12,869.77 3
PY2020 Recipient $5,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

98 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient JAZZ PHARMACEUTICALS INC. $3,877.90 12/17/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734746
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $118.70 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745314
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5.76 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745316
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $66.00 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745318
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.99 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745320
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $91.22 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745322
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $44.00 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745324
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $32.70 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745326
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $46.87 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745328
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18.70 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745330
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9.03 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745332
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.84 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745334
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5.76 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745336
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $74.80 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745338
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.84 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745340
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $28.05 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745342
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.32 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745344
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.16 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745346
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $112.20 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745348
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.84 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745350
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8.12 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745352
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.80 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745354
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.98 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745356
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.42 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745358
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $37.40 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745360
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.32 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745362
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $44.00 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745364
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.98 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745366
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12.83 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745368
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7.13 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745370
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $221.38 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745372
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $44.00 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745374
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $119.28 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745376
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7.13 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745378
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $90.84 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745380
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.04 11/24/2025 Non-covered Recipient Entity
TriValley Sleep Center
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233745382
Recipient JAZZ PHARMACEUTICALS INC. $520.00 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734730
Recipient JAZZ PHARMACEUTICALS INC. $1,865.50 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734732
Recipient JAZZ PHARMACEUTICALS INC. $19,223.10 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734736
Recipient JAZZ PHARMACEUTICALS INC. $483.60 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734738
Recipient JAZZ PHARMACEUTICALS INC. $379.60 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734750
Recipient JAZZ PHARMACEUTICALS INC. $422.50 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734752
Recipient JAZZ PHARMACEUTICALS INC. $253.50 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734758
Recipient JAZZ PHARMACEUTICALS INC. $1,653.60 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734760
Recipient JAZZ PHARMACEUTICALS INC. $509.60 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734766
Recipient JAZZ PHARMACEUTICALS INC. $1,300.00 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734768
Recipient JAZZ PHARMACEUTICALS INC. $163.80 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734772
Recipient JAZZ PHARMACEUTICALS INC. $11,398.40 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734774
Recipient JAZZ PHARMACEUTICALS INC. $12,896.00 10/24/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734776
Recipient JAZZ PHARMACEUTICALS INC. $8,327.00 10/13/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734734
Recipient JAZZ PHARMACEUTICALS INC. $2,479.00 10/13/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734740
Recipient JAZZ PHARMACEUTICALS INC. $1,500.00 10/13/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734742
Recipient JAZZ PHARMACEUTICALS INC. $15,600.00 10/13/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734744
Recipient JAZZ PHARMACEUTICALS INC. $1,440.00 10/13/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734748
Recipient JAZZ PHARMACEUTICALS INC. $2,500.00 10/13/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734754
Recipient JAZZ PHARMACEUTICALS INC. $3,000.00 10/13/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734756
Recipient JAZZ PHARMACEUTICALS INC. $5,000.00 10/13/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734762
Recipient JAZZ PHARMACEUTICALS INC. $2,000.00 10/13/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734764
Recipient JAZZ PHARMACEUTICALS INC. $3,500.00 10/13/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734770
Recipient JAZZ PHARMACEUTICALS INC. $1,400.00 10/13/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734778
Recipient JAZZ PHARMACEUTICALS INC. $33,120.69 09/26/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734728
Recipient JAZZ PHARMACEUTICALS INC. $5,835.70 09/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734720
Recipient JAZZ PHARMACEUTICALS INC. $413.66 09/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734724
Recipient JAZZ PHARMACEUTICALS INC. $3,212.30 09/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734726
Principal investigator 1 Noctrix Health, Inc. $10,975.00 09/03/2025 Non-covered Recipient Entity
Haramandeep Singh MD INC
THRIVE No dispute reported 06/30/2026 1254628931
Recipient JAZZ PHARMACEUTICALS INC. $3,000.00 07/23/2025 Covered Recipient Physician An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233734712
Recipient JAZZ PHARMACEUTICALS INC. $500.00 07/23/2025 Covered Recipient Physician An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233734716
Recipient JAZZ PHARMACEUTICALS INC. $4,199.00 07/23/2025 Covered Recipient Physician An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233734718
Recipient JAZZ PHARMACEUTICALS INC. $2,500.00 07/23/2025 Covered Recipient Physician An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233734722
Recipient JAZZ PHARMACEUTICALS INC. $1,583.66 07/11/2025 Covered Recipient Physician An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233734714
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.96 06/11/2025 Non-covered Recipient Entity
TriValley Sleep Center
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233745308
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16.05 06/11/2025 Non-covered Recipient Entity
TriValley Sleep Center
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233745310
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.72 06/11/2025 Non-covered Recipient Entity
TriValley Sleep Center
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233745312
Recipient JAZZ PHARMACEUTICALS INC. $1,110.72 03/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734692
Recipient JAZZ PHARMACEUTICALS INC. $1,388.40 03/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734698
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 02/28/2025 Non-covered Recipient Entity
TriValley Sleep Center
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233745298
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 02/28/2025 Non-covered Recipient Entity
TriValley Sleep Center
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233745304
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 02/28/2025 Non-covered Recipient Entity
TriValley Sleep Center
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233745306
Recipient JAZZ PHARMACEUTICALS INC. $9,972.30 02/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734674
Recipient JAZZ PHARMACEUTICALS INC. $852.80 02/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734688
Recipient JAZZ PHARMACEUTICALS INC. $8,711.30 02/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734690
Recipient JAZZ PHARMACEUTICALS INC. $6,740.11 02/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734696
Recipient JAZZ PHARMACEUTICALS INC. $852.80 02/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734700
Recipient JAZZ PHARMACEUTICALS INC. $980.20 02/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734702
Recipient JAZZ PHARMACEUTICALS INC. $980.20 02/03/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734710
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
TriValley Sleep Center
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233745296
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
TriValley Sleep Center
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233745300
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
TriValley Sleep Center
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233745302
Recipient JAZZ PHARMACEUTICALS INC. $1,342.90 01/17/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734676
Recipient JAZZ PHARMACEUTICALS INC. $1,342.90 01/17/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734678
Recipient JAZZ PHARMACEUTICALS INC. $1,342.90 01/17/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734680
Recipient JAZZ PHARMACEUTICALS INC. $8,711.30 01/17/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734682
Recipient JAZZ PHARMACEUTICALS INC. $1,342.90 01/17/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734684
Recipient JAZZ PHARMACEUTICALS INC. $1,342.90 01/17/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734686
Recipient JAZZ PHARMACEUTICALS INC. $8,711.30 01/17/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734694
Recipient JAZZ PHARMACEUTICALS INC. $8,711.30 01/17/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734704
Recipient JAZZ PHARMACEUTICALS INC. $1,342.90 01/17/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734706
Recipient JAZZ PHARMACEUTICALS INC. $1,342.90 01/17/2025 Covered Recipient Physician A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233734708